CUMBERLAND PHARMACEUTICALS INC - 8-K Filing

Cumberland Pharmaceuticals reports Q3 2026 net income of $77.8 million following $100 million strategic transaction with Apotex Health. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits (d) ExhibitsExhibit No)

SEC EDGAR · November 10, 2026, 22:06 UTC

Tickers: $CPIX

Read the full article at SEC EDGAR

Part of the story InMed Pharmaceuticals Inc. - 8-K Filing (3 articles)

More Regulatory news

DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC
Beyond Air, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:17 UTC
Carter Bankshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:12 UTC